David Auerbach is the newly appointed Head of Business Projects – Oncology R&D Business Planning & Operations at AstraZeneca
July 21, 2020
David Auerbach is the newly appointed Head of Business Projects within the Oncology R&D Business Planning & Operations organization at AstraZeneca. He directly supports the Executive Vice President of Oncology R&D and works closely with the leadership team to deliver strategic and operational priorities and drive the business.
He previously was Head of Business Planning & Operations within Early Oncology R&D. Prior to this role, he managed complex projects and alliances at MedImmune. Prior to MedImmune, he worked in life sciences management consulting at Capgemini Consulting, assay development at Teva Pharmaceuticals and HIV research at the National Institutes of Health. He has a dual MBA and MS in Biotechnology graduate degree from Johns Hopkins University.
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
Latest posts by Chris Frew (see all)
- Veralox Therapeutics Appoints Life Sciences Industry Veteran Alex Martin as Chairman of the Board of Directors - September 17, 2020
- MaxCyte Appoints Amanda L. Murphy as Chief Financial Officer - September 17, 2020
- Graybug Vision files for $86 Million IPO on NASDAQ - September 14, 2020